ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "autoimmune diseases"

  • Abstract Number: 0800 • ACR Convergence 2020

    A Randomized, Double-Blind, Phase 3 Study to Compare the Efficacy and Safety of a Proposed High Concentration (100 mg/mL) Adalimumab Biosimilar (CT-P17) with Reference Adalimumab in Patients with Moderate-to-Severe Active Rheumatoid Arthritis

    Jonathan Kay1, Janusz Jaworski2, Rafal Wojciechowski3, Piotr Wiland4, Anna Dudek5, Marek Krogulec6, Slawomir Jeka7, Agnieszka Zielinska8, Jakub Trefler9, Katarzyna Bartnicka-Maslowska10, Magdalena Krajewska-Wlodarczyk11, Piotr Klimiuk12, Daniel Furst*13, SangJoon Lee14, YunJu Bae14, GoEun Yang14, JaeKyoung Yoo14, HyunJin Lee14 and Edward C Keystone15, 1University of Massachusetts Medical School, Worcester, MA, 2Reumatika-Centrum Reumatologii, Warsaw, Poland, 3University Hospital No 2, Bydgoszcz, Poland, 4Medical Univeristy, Wroclaw, Poland, 5Centrum Medyczne AMED, Warsaw, Poland, 6Rheumatology Clinic NZOZ Lecznica MAK-MED, Nadarzyn, Poland, 72nd Univ Hospital, CM UMK, Bydgoszcz, Poland, 8Medycyna Kliniczna Marzena Waszczak-Jeka, Warsaw, Poland, 9Reuma Centrum, Warsaw, Poland, 10Centrum Medyczne AMED oddzial w Łodzi, Łódź, Poland, 11University of Warmia and Mazury, Olsztyn, Poland, 12Medical University of Białystok and Gabinet Internistyczno-Reumatologiczny Piotr Adrian Klimiuk, Białystok, Poland, 13Department of Medicine, Division of Rheumatology, University of California at Los Angeles, Los Angeles, California, USA, Los Angeles, CA, 14Celltrion, Inc., Incheon, Republic of Korea, 15Mount Sinai Hospital, Toronto, ON, Canada

    Background/Purpose: CT-P17 (100 mg/mL) is the first proposed biosimilar of the high concentration and citrate-free formulation of reference adalimumab. The purpose of this study was…
  • Abstract Number: 1043 • ACR Convergence 2020

    Ocular Scleral Pathology and Immune-Mediated Inflammatory Diseases. Study of 170 Patients from a Single Universitary Center

    Lara Sanchez-Bilbao1, Inigo Gonzalez-Mazon2, José Luis Martín-Varillas3, David Martinez-Lopez4, Carmen Alvarez-Reguera1, Alba Herrero Morant1, Rosalia Demetrio-Pablo1, Vanesa Calvo-Río1, Miguel Ángel González-Gay5 and Ricardo Blanco1, 1Hospital Universitario Marques de Valdecilla, Santander, Spain, 2Hospital Universitario Marques de Valdecilla, Bezana, Spain, 3Hospital Sierrallana, Torrelavega, Spain, 4Hospital Universitario Marques de Valdecilla, Santander (SPAIN), Spain, 5Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain

    Background/Purpose: Ocular scleral pathology (OSP) includes episcleritis and scleritis. Episcleritis is generally a benign disease with a self-limited course, while scleritis is a more severe…
  • Abstract Number: 1261 • ACR Convergence 2020

    Antiphospholipid Patterns Predict the Risk of Thrombosis in Systemic Lupus Erythematosus

    Selcan Demir1, Jessica Li2, Laurence Magder3 and Michelle Petri4, 1Hacettepe University Faculty of Medicine, Ankara, Ankara, Turkey, 2Johns Hopkins University, Baltimore, MD, 3University of Maryland, Baltimore, Baltimore, MD, 4Johns Hopkins University School of Medicine, Timonium, MD

    Background/Purpose: Antiphospholipid syndrome (APS) has been classified as the development of venous and/or arterial thromboses, and/or pregnancy morbidity, in the presence of persistently raised levels…
  • Abstract Number: 1415 • ACR Convergence 2020

    Murine Roseolovirus Induces Autoimmune Disease and Development of Autoreactive T Cells and Autoantibodies

    Tarin Bigley1, Jose Saenz2, Li-Ping Yang2, Jason Mills2 and Wayne Yokoyama2, 1Washington University in St. Louis, Saint Louis, MO, 2Washington University in St. Louis, St. Louis, MO

    Background/Purpose: Murine roseolovirus (MRV) is a recently sequenced beta-herpesvirus that is a natural murine pathogen and is genetically highly related to HHV6 and HHV7. The…
  • Abstract Number: 1578 • ACR Convergence 2020

    Rituximab Hypersensitivity in Rheumatic and Inflammatory Diseases: Role of Skin Testing

    Sravani Penumarty1, Javier Quintero Betancourt2, Eugenio Capitle2 and Reena Khianey2, 1Rutgers, Eastvale, CA, 2Rutgers, Newark, NJ

    Background/Purpose: Infusion-related reactions have been reported with rituximab, a monoclonal antibody targeting the CD20 antigen on B cells, and may result in discontinuation of the…
  • Abstract Number: 2037 • ACR Convergence 2020

    Geographic Distribution and Environmental Triggers of Systemic Sclerosis in Massachusetts

    Anastasiya Muntyanu1, Bina Kassamali2, Ruth Ann Vleugels3 and Avery LaChance3, 1McGill University, Montreal, QC, Canada, 2Harvard Medical School, Brigham and Women's Hospital, Boston, MA, 3Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Systemic sclerosis (SSc) is a chronic autoimmune sclerosing disease with a 10-year survival rate of less than 65%. This rate has remained unchanged for…
  • Abstract Number: 147 • 2020 Pediatric Rheumatology Symposium

    Familial Clustering of Immune-mediated Diseases in Children with Abrupt-onset OCD

    Avis Chan 1, Tiffany Phu 1, Bahare Farhadian 2, Theresa Willett 3, Melissa Silverman 1, Paula Tran 1, Margo Thienemann 3 and Jennifer Frankovich4, 1Stanford University School of Medicine, Palo Alto, 2Stanford Immune Behavioral Health Clinic and PANS Research Program at Lucile Packard Children's Hospital, Palo Alto, 3Stanford University School of Medicine, Palo Alto, California, 4Stanford

    Background/Purpose: Recent epidemiologic studies have reported increased rates of immune-mediated comorbidities among first-degree relatives of patients with OCD and tic disorders.(Mataix-Cols et al., Mol Psychiatry…
  • Abstract Number: L19 • 2019 ACR/ARP Annual Meeting

    Ianalumab (VAY736), a Dual Mode of Action Biologic Combining BAFF Receptor Inhibition with B Cell Depletion, for Treatment of Primary Sjögren’s Syndrome: Results of an International Randomized, Placebo Controlled Dose Range Finding Study in 190 Patients

    Simon Bowman1, Robert Fox 2, Thomas Dörner 3, Xavier Mariette 4, Athena Papas 5, Thomas Grader-Beck 6, Benjamin A. Fisher 7, Filipe Barcelos 8, Salvatore De Vita 9, Hendrik Schulze-Koops 10, Robert J. Moots 11, Guido Junge 12, Janice Woznicki 13, Monika Sopala 12, Wen-Lin Luo 13 and Wolfgang Hueber 12, 1University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom, 2Scripps Memorial Hospital and Research Institute, La Jolla, California, 3Charite Universitätsmedizin Berlin and DRFZ, Berlin, Germany, 4Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France, 5Tufts School of Dental Medicine, Massachusetts, 6Johns Hopkins University, Baltimore, 7University Hospitals Birmingham NHS Foundation Trust, Birmingham Biomedical Research Centre, Birmingham, United Kingdom, 8Nova Medical School, Hospital Cuf Descobertas, Instituto Português de Reumatologia,, Lisbon, Portugal, 9Rheumatology Clinic, Udine University Hospital, Department of Medical Area, University of Udine, Udine, Italy, Udine, Italy, 10Department of Rheumatology/Clinical Immunology, Ludwig-Maximilians-University Munich, Munich, Germany, 11Institute of Ageing and Chronic Disease, Liverpool, United Kingdom, 12Novartis Pharma AG, basel, Switzerland, 13Novartis Pharmaceuticals Corporation, New Jersey

    Background/Purpose: Primary Sjogren’s syndrome (pSS) is a multi-organ autoimmune disease primarily affecting excretory glands and characterized by B-cell hyperactivity. No approved systemic treatments are available.…
  • Abstract Number: 104 • 2019 ACR/ARP Annual Meeting

    Novel, Selective, Orally Active PAD4 Inhibitors for the Treatment of Autoimmune Disorders

    Santosh Vishwakarma1, Gurulingappa Hallur 1, Himanshu Agrawal 1, Sharad Singh 1, Annasaheb Kalange 1, Seema Chikkur Gangadhar 1, Shuvranshu PraharaJ 1, Nafees Ahmad Quresh 1, Srikanth Kanagal Gopinath 1, Krishnakumar V 1, Sameer Mahmood 1, Rudresh G 1, Mohd Zainuddin 1, Rajendra Kristam 1, Ishtiyaque Ahmad 1, Ramachandraiah Gosu 1, Purra Buchi Reddy 1, N V S K Rao 1, Saloni Mehra 2, Jeyaraj D A 1, Takeshi Yura 1, Saravanakumar dhakshinamoorthy 1, Sriram Rajagopal 1, Dhanalakshmi Sivanandhan 3 and Sridharan Rajagopal 3, 1Jubilant Biosys, Bangalore, India, 2Jubilant Chemsys, Noida, India, 3Jubilant Therapeutics, Bangalore, India

    Background/Purpose: Citrullination of proteins is catalyzed by a family of enzymes called the peptidylarginine deiminases (PADs). While the citrullinated proteins may have physiological roles in differentiation,…
  • Abstract Number: 1650 • 2019 ACR/ARP Annual Meeting

    Baseline Skin Score, Older Age and CD34-selection Influence the Outcome of Autologous Stem Cell Transplantation for Systemic Sclerosis – Results of a Prospective Non-interventional Study from the European Society for Blood & Marrow Transplantation (EBMT)

    Joerg Henes1, Maria Carolina Oliveira 2, Myriam Labopin 3, Manuela Badoglio 4, Hans Ulrich Scherer 5, Nicoletta Del Papa 6, Thomas Daikeler 7, Marc Schmalzing 8, Roland Schroers 9, Thierry Martin 10, Grégory Pugnet 11, Belinda Simoes 12, David Michonneau 13, Erik Marijt 14, Bruno Lioure 15, Jacques Olivier Bay 16, John Snowden 17, Montserrat Rovira 18, Anne Huynh 19, Francesco Onida 20, Lothar Kanz 1, Zora Marjanovic 21 and Dominique Farge 22, 1University Hospital Tuebingen, Department of Internal Medicine II (Oncology, Haematology, Immunology and Rheumatology), Tuebingen, Germany, 2Ribeirão Preto Medical School, University of São Paulo, Sao Paulo, Brazil, 3EBMT Paris Study Office, Saint Antoine Hospital, Université Pierre et Marie Curie, Paris, France, 4EBMT Paris Study Office, Hôpital St Antoine, Paris, France, 5Leiden University Medical Center, Department of Rheumatology, Leiden, Netherlands, 6Scleroderma Clinic, Osp. G. Pini, Department of Rheumatology, Milan, Italy, 7University and University Hospital of Basel, Department of Rheumatology, Basel, Switzerland, 8Universitätsklinikum Würzburg, Department of Rheumatology/ Clinical Immunology, Wuerzburg, Germany, 9University Hospital of Bochum, Med. Klinik, Bochum, Germany, 10Hôpitaux Universitaires de Strasbourg Service de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-Immunes Systémiques Rares Est-Sud-Ouest (RESO), Strasbourg, France, 11CHU de Toulouse, Hôpital Purpan, Service de Médecine Interne, Toulouse, France, 12Ribeirão Preto Medical School, University of São Paulo, Division of Hematology, Sao Paulo, Brazil, 13Hôpital Saint Louis & Université Paris 7, Denis Diderot, Department of Hematology, Paris, France, 14Leiden University Medical Center, Department of Hematology, Leiden, Netherlands, 15Strasbourg University Hospital, Department of Hematology, Strasbourg, France, 16CHU de Clermont Ferrand, Department of Hematology, Clermont Ferrand, France, 17Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom, 18Hospital Clínic of Barcelona, Department of Haematology, Barcelona, Spain, 19UCT Oncopole, Department of Haematology, Toulouse, France, 20Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy, 21Saint Antoine Hospital, Department of Haematology, Paris, France, 22Hôpital Saint-Louis, AP-HP Assistance Publique des Hôpitaux de Paris, Centre de Référence des Maladies Auto-Immunes Systémiques Rares d’Ile-de-France, Filière ‘FAI2R’, Unité de Médecine Interne: Maladies Auto-immunes et Pathologie Vasculaire (UF 04), Université de Paris, EA 3518, Paris, France; Department of Medicine, McGill University, Montreal, QC, Canada, Paris, France

    Background/Purpose: TThree randomized controlled trials in systemic sclerosis (SSc) demonstrated that autologous hematopoietic stem cell transplantation (aHSCT) is superior to standard cyclophosphamide therapy. This EBMT…
  • Abstract Number: 120 • 2019 ACR/ARP Annual Meeting

    Administration of a CD45 Antibody Drug Conjugate as a Novel, Targeted Approach to Achieve Immune System Reset: A Single Dose of CD45-targeted ADC Safely Conditions for Autologous Transplant and Ameliorates Disease in Multiple Models of Autoimmune Disease

    Geoffrey Gillard1, Jennifer Proctor 1, Melissa Brooks 1, Tahirih Lamothe 1, Sharon Hyzy 1, Sean McDonough 1, Rahul Palchaudhuri 2, Anjali Bhat 1, Ganapathy Sarma 1, Prashant Bhattarai 1, Pranoti Sawant 1, Brad Pearse 1, Charlotte McDonagh 1, Anthony Boitano 1 and Michael Cooke 1, 1Magenta Therapeutics, Cambridge, MA, 2Magenta Therapeutics, Cambridge

    Background/Purpose: Autologous hematopoietic stem cell transplant (autoHSCT) is a highly effective treatment in selected patients with autoimmune diseases. AutoHSCT can induce long-term remission (up to…
  • Abstract Number: 1807 • 2019 ACR/ARP Annual Meeting

    Teprotumumab, a Novel Biologic for Active Thyroid Eye Disease

    George J. Kahaly 1, Saba Sile 2, Elizabeth H.Z. Thompson 2, Thomas Vescio 3, Renee Perdok 3, Jeffrey W. Sherman3, Terry J. Smith 4 and Raymond S. Douglas 5, 1Johannes Gutenberg University Medical Center, Mainz, Germany, 2Horizon Therapeutics plc, Brisbane, CA, 3Horizon Therapeutics plc, Lake Forest, IL, 4University of Michigan Kellogg Eye Center, Ann Arbor, MI, 5Cedars Sinai Medical Center, Los Angeles, CA

    Background/Purpose: Thyroid eye disease (TED) is a debilitating autoimmune disorder characterized by inflammation and exophthalmia along with significantly altered appearance and vision changes. TED is…
  • Abstract Number: 253 • 2019 ACR/ARP Annual Meeting

    A Systematic Review and Meta-analysis of Observational Studies Reporting on the Use of Checkpoint Inhibitors in Patients with Cancer and Pre-existing Autoimmune Disease

    Maria Lopez-Olivo1, Noha Abdel-Wahab 1 and Maria E. Suárez-Almazor 2, 1The University of Texas, MD Anderson Cancer Center, Houston, TX, 2Department of Rheumatology/Clinical Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX , USA., Houston, TX

    Background/Purpose: Immune checkpoint inhibitors (ICI) are increasingly used in the treatment of cancer. To date, no clinical trials exist evaluating the use of ICI in…
  • Abstract Number: 1833 • 2019 ACR/ARP Annual Meeting

    Efficacy and Safety of Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease by Use of Mycophenolate at Baseline: Subgroup Analysis of the SENSCIS Trial

    Kristin Highland1, Oliver Distler 2, Masataka Kuwana 3, Yannick Allanore 4, Shervin Assassi 5, Arata Azuma 6, Arnaud Bourdin 7, Christopher Denton 8, Jörg Distler 9, Anna Maria Hoffmann-Vold 10, Dinesh Khanna 11, Maureen Mayes 5, Ganesh Raghu 12, Madelon Vonk 13, Martina Gahlemann 14, Mannaig Girard 15, Susanne Stowasser 16, Donald Zoz 17, Aryeh Fischer 18 and Toby Maher 19, 1Cleveland Clinic, Cleveland, Ohio, USA, Cleveland, OH, 2Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland, 3Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, Bunkyo-ku, Tokyo, Japan, 4Dept. of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, Paris, France, 5Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, Texas, USA, Houston, TX, 6Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan, Tokyo, Japan, 7PhyMedExp, University of Montpellier, INSERM U1046, CNRS UMR 9214 and Department of Respiratory Diseases, University of Montpellier, CHU Montpellier, Montpellier, France, Montpellier, 8University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, UK, London, United Kingdom, 9Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, Erlangen, Germany, 10Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, 11Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, 12University of Washington, Seattle, USA, Seattle, 13Department of Rheumatology, Radboud University Medical Center, Nijmegen, The Netherlands, Nijmegen, Gelderland, Netherlands, 14Boehringer Ingelheim (Schweiz) GmbH, Basel, Switzerland, Basel, Switzerland, 15Boehringer Ingelheim France S.A.S., Reims, France, Reims, France, 16Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, 17Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA, Ridgefield, CT, 18University of Colorado School of Medicine, Denver, Colorado, USA, Denver, CO, 19National Heart and Lung Institute, Imperial College London, UK and National Institute for Health Research Clinical Research Facility, Royal Brompton Hospital, London, UK, London, United Kingdom

    Background/Purpose: In the SENSCIS trial in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), nintedanib reduced the annual rate of decline in forced vital capacity…
  • Abstract Number: 374 • 2019 ACR/ARP Annual Meeting

    The INBUILD Trial of Nintedanib in Patients with Progressive Fibrosing Interstitial Lung Diseases: Subgroup with Autoimmune Diseases

    Eric Matteson1, Clive Kelly 2, Jörg Distler 3, Anna Maria Hoffmann-Vold 4, James Seibold 5, Shikha Mittoo 6, Oliver Distler 7, Rainer-Georg Goeldner 8, Rozsa Schlenker-Herceg 9, Susanne Stowasser 10, Manuel Quaresma 10 and Kevin Flaherty 11, 1Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA, Rochester, 2Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK, Newcastle, United Kingdom, 3Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, Erlangen, Germany, 4Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, 5Scleroderma Research Consultants LLC, Aiken, South Carolina, USA, Aiken, 6University Health Network, Toronto, Ontario, Canada, Toronto, Canada, 7Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland, 8Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany, Biberach, Germany, 9Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA, Ridgefield, 10Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, 11University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, MI

    Background/Purpose: Some patients with autoimmune disease develop progressive fibrosing interstitial lung disease (ILD) characterized by increasing fibrosis on HRCT, decline in lung function, worsening symptoms…
  • « Previous Page
  • 1
  • …
  • 67
  • 68
  • 69
  • 70
  • 71
  • …
  • 80
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology